David McGiffin

Prof. David McGiffin

The Alfred Hospital
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DMDavid McGiffin
David McGiffin
CKChristina E. Kure
Christina E. Kure
PMPeter S. Macdonald
Peter S. Macdonald
PJPaul C. Jansz
Paul C. Jansz
SESam Emmanuel
Sam Emmanuel
DKDavid M. Kaye
David M. Kaye

1 March 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DMDavid McGiffin
David McGiffin
CKChristina Kure
Christina Kure
JMJanelle McLean
Janelle McLean
SMSilvana Marasco
Silvana Marasco
PBPeter Bergin
Peter Bergin
DKDavid Kaye
David Kaye

25 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YQYue Qu
Yue Qu
APAnton Peleg
Anton Peleg
DMDavid McGiffin
David McGiffin
Ventricular assist device (VAD)-specific infections, in particular, driveline infections, are a concerning complication of VAD implantation that often results in significant morbidity and even mortality. The presence of a percutaneous driveline at the skin exit-site and in the subcutaneous tunnel allows biofilm formation and migration by many bacterial and fungal pathogens. Biofilm formation is an important microbial strategy, providing a shield against antimicrobial treatment and human immune responses; biofilm migration facilitates the extension of infection to deeper tissues such as the pump pocket and the bloodstream. Despite the introduction of multiple preventative strategies, driveline infections still occur with a high prevalence of ~10–20% per year and their treatment outcomes are frequently unsatisfactory. Clinical diagnosis, prevention and management of driveline infections are being targeted to specific microbial pathogens grown as biofilms at the driveline exit-site or in the driveline tunnel. The purpose of this review is to improve the understanding of VAD-specific infections, from basic “bench” knowledge to clinical “bedside” experience, with a specific focus on the role of biofilms in driveline infections.

1 October 2018 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
SMSilvana F. Marasco
Silvana F. Marasco
LFLouise Fuller
Louise Fuller
AZAdam Zimmet
Adam Zimmet
DMDavid McGiffin
David McGiffin
MSMichael Seitz
Michael Seitz
MBMichael Bailey
Michael Bailey

7 April 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
LHLouise See Hoe
Louise See Hoe
GBGianluigi Li Bassi
Gianluigi Li Bassi
WKWildi Karin
Wildi Karin
MPMargaret Passmore
Margaret Passmore
MBMahe Bouquet
Mahe Bouquet
JFJohn F. Fraser
John F. Fraser
The global shortage of donor hearts available for transplantation is a major problem for the treatment of end-stage heart failure. The ischemic time for donor hearts using traditional preservation by standard static cold storage (SCS) is limited to approximately 4 hours, beyond which the risk for primary graft dysfunction (PGD) significantly increases. Hypothermic machine perfusion (HMP) of donor hearts has been proposed to safely extend ischemic time without increasing the risk of PGD. Using our sheep model of 24 hours brain death (BD) followed by orthotopic heart transplantation (HTx), we examined post-transplant outcomes in recipients following donor heart preservation by HMP for 8 hours, compared to donor heart preservation for 2 hours by either SCS or HMP. Following HTx, all HMP recipients (both 2 hours and 8 hours groups) survived to the end of the study (6 hours after transplantation and successful weaning from cardiopulmonary bypass), required less vasoactive support for hemodynamic stability, and exhibited superior metabolic, fluid status and inflammatory profiles compared to SCS recipients. Contractile function and cardiac damage (troponin I release and histological assessment) was comparable between groups. Overall, compared to current clinical SCS, recipient outcomes following transplantation are not adversely impacted by extending HMP to 8 hours. These results have important implications for clinical transplantation where longer ischemic times may be required (e.g., complex surgical cases, transport across long distances). Additionally, HMP may allow safe preservation of "marginal" donor hearts that are more susceptible to myocardial injury and facilitate increased utilization of these hearts for transplantation.

1 November 2002 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
SASujood Ahmed
Sujood Ahmed
NNNavin C Nanda
Navin C Nanda
AMAndrew P Miller
Andrew P Miller
RNRajasekhar Nekkanti
Rajasekhar Nekkanti
AYAbdalla M Yousif
Abdalla M Yousif
DMDavid McGiffin
David McGiffin